Phase II trial: Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer

Source: Lancet Oncology Area: News Inhibition of oestrogen receptor is a mainstay of treatment for oestrogen-receptor-positive breast cancer but intrinsic and acquired resistance undermine the long-term effectiveness of endocrine treatments and lead to relapses in early stage disease. This has led to a drive to develop targeted therapies and integrate them into existing treatment strategies. Oestrogen receptor signalling is linked to many other cell signalling pathways, including those related to growth hormones and insulin-like growth factor (IGF). IGF-1 and IGF-2 bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. In The Lancet Oncology, researchers report the first randomised study of IGF-1R inhibition with ganitumab combined with hormonal treatment for endocrine-resistant metastatic breast cancer.   The phase II trial was conducted in outpatient clinics and hospitals and enrolled 156 postmenopausal women with ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news